biostudies-literatureUnknown14Liang H<h4>Objective</h4>This study aimed to evaluate the clinical utility of <i>PAX1/JAM3</i> methylation (CISCER) test in triaging high-risk human papillomavirus (hrHPV)-positive women.<h4>Methods</h4>We enrolled women who underwent opportunistic screening at Cervical Disease outpatient clinics of Xuzhou Maternity and Child Health Hospital, and Yueyang Central Hospital from December 2022 to May 2024. The effectiveness of CISCER and cytology tests in triaging hrHPV+ patients was analyzed.<h4>Results</h4>Among the 436 study participants, 283 (64.9%) had no cervical intraepithelial neoplasia (CIN), while 53 (12.2%) had CIN1, 40 (9.2%) had CIN2, 34 (7.8%) had CIN3, and 26 (5.9%) had cervical cancers. The CISCER tests identified all cases of cervical cancer, particularly 2 hrHPV-negative adenocarcinFrontiers in oncology1481626https://www.ebi.ac.uk/biostudies/studies/S-EPMC11628385biostudies-literatureAssessment of <i>PAX1</i> and <i>JAM3</i> methylation triage efficacy across HPV genotypes and age groups in high-risk HPV-positive women in China.PMC11628385Liu YWu ZLiu JLiang HYin SLiu PDou QChen YWang HJiang MWang YWang JfalseAssessment of <i>PAX1</i> and <i>JAM3</i> methylation triage efficacy across HPV genotypes and age groups in high-risk HPV-positive women in China.<h4>Objective</h4>This study aimed to evaluate the clinical utility of <i>PAX1/JAM3</i> methylation (CISCER) test in triaging high-risk human papillomavirus (hrHPV)-positive women.<h4>Methods</h4>We enrolled women who underwent opportunistic screening at Cervical Disease outpatient clinics of Xuzhou Maternity and Child Health Hospital, and Yueyang Central Hospital from December 2022 to May 2024. The effectiveness of CISCER and cytology tests in triaging hrHPV+ patients was analyzed.<h4>Results</h4>Among the 436 study participants, 283 (64.9%) had no cervical intraepithelial neoplasia (CIN), while 53 (12.2%) had CIN1, 40 (9.2%) had CIN2, 34 (7.8%) had CIN3, and 26 (5.9%) had cervical cancers. The CISCER tests identified all cases of cervical cancer, particularly 2 hrHPV-negative adenocarcin2024-01-01T00:00:00Z20242025-04-04T02:33:37.495Z2025-04-04T02:33:37.495ZS-EPMC116283853965979410.3389/fonc.2024.1481626